Skip to main content

Table 3 Clinical characteristics of the study population

From: A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain

Predominant symptomPercentage
Severe dysmenorrhea85.2%
Moderate dysmenorrhea14.8%
Severe dyspareunia18.5%
Moderate dyspareunia29.6%
Mild dyspareunia3.7%